Collegium Pharmaceutical, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Collegium Pharmaceutical, Inc. (COLL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $14.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $14.48M, a 33.89% increase year-over-year.
- Collegium Pharmaceutical, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.88M, a 5.59% decline year-over-year.
- Collegium Pharmaceutical, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $9.81M, a 34.09% increase year-over-year.
- Collegium Pharmaceutical, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $10.82M, a 8.05% increase year-over-year.
- Collegium Pharmaceutical, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $41.91M, a 29.34% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $32.40M, a 231328.57% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $14.00K, a 99.94% decline from fiscal 2022.
- Collegium Pharmaceutical, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $22.87M, a 5.69% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $14.48M 10-Q · filed 2026-08-06 | $25.36M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $10.88M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $41.91M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $9.81M 10-Q · filed 2025-11-06 | $20.63M derived: sum of 2 quarters · filed 2026-08-06 | $32.15M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $10.82M 10-Q · filed 2026-08-06 | $22.34M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $11.52M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $32.40M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $7.32M 10-Q · filed 2025-11-06 | $17.33M derived: sum of 2 quarters · filed 2025-11-06 | $24.80M derived: sum of 3 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $10.01M 10-Q · filed 2025-11-06 | $17.49M derived: sum of 2 quarters · filed 2025-11-06 | |||
| 2024-03-31 | $7.47M 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $14.00K 10-K · filed 2026-02-26 | $27.14M 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $7.03M 10-Q · filed 2024-11-07 | $14.10M derived: sum of 2 quarters · filed 2024-11-07 | $20.13M derived: sum of 3 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $7.07M 10-Q · filed 2024-11-07 | $13.11M derived: sum of 2 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $6.04M 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $22.87M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $5.38M 10-Q · filed 2023-11-07 | $11.07M derived: sum of 2 quarters · filed 2023-11-07 | $17.20M derived: sum of 3 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $5.69M 10-Q · filed 2023-11-07 | $11.83M derived: sum of 2 quarters · filed 2023-11-07 | |||
| 2022-03-31 | $6.13M 10-Q · filed 2023-11-07 | ||||
| 2021-12-31 | $24.25M 10-K · filed 2024-02-22 | ||||
| 2021-09-30 | $5.95M 10-Q · filed 2022-11-03 | $12.46M derived: sum of 2 quarters · filed 2022-11-03 | $19.34M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $6.52M 10-Q · filed 2022-11-03 | $13.39M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $6.88M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $21.91M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $5.17M 10-Q · filed 2021-11-04 | $10.75M derived: sum of 2 quarters · filed 2021-11-04 | $15.70M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $5.58M 10-Q · filed 2021-11-04 | $10.54M derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | $4.95M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | $16.53M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $4.14M 10-Q · filed 2020-11-05 | $8.30M derived: sum of 2 quarters · filed 2020-11-05 | $12.56M derived: sum of 3 quarters · filed 2020-11-05 | $16.16M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $4.16M 10-Q · filed 2020-11-05 | $8.43M derived: sum of 2 quarters · filed 2020-11-05 | $12.02M derived: sum of 3 quarters · filed 2021-02-25 | $15.95M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $4.26M 10-Q · filed 2020-11-05 | $7.86M derived: sum of 2 quarters · filed 2021-02-25 | $11.79M derived: sum of 3 quarters · filed 2021-02-25 | $15.31M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $7.52M derived: sum of 2 quarters · filed 2021-02-25 | $11.05M derived: sum of 3 quarters · filed 2021-02-25 | $13.78M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $3.93M 10-Q · filed 2019-11-06 | $7.45M derived: sum of 2 quarters · filed 2019-11-06 | $10.18M 10-Q · filed 2018-11-08 | $12.26M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $3.53M 10-Q · filed 2019-11-06 | $6.25M 10-Q · filed 2018-08-08 | $8.33M derived: sum of 3 quarters · filed 2020-02-27 | $10.43M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $2.73M 10-Q · filed 2019-11-06 | $4.81M derived: sum of 2 quarters · filed 2020-02-27 | $6.91M derived: sum of 3 quarters · filed 2020-02-27 | $8.85M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $4.18M derived: sum of 2 quarters · filed 2020-02-27 | $6.12M derived: sum of 3 quarters · filed 2020-02-27 | $7.95M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $4.05M derived: sum of 2 quarters · filed 2017-11-08 | $5.87M 10-Q · filed 2017-11-08 | $7.52M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $3.77M 10-Q · filed 2017-08-09 | $5.42M derived: sum of 3 quarters · filed 2019-02-27 | $7.06M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $1.82M 10-Q · filed 2017-05-10 | $3.47M derived: sum of 2 quarters · filed 2019-02-27 | $5.11M derived: sum of 3 quarters · filed 2019-02-27 | $6.51M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $3.29M derived: sum of 2 quarters · filed 2019-02-27 | $4.69M derived: sum of 3 quarters · filed 2019-02-27 | $5.79M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $3.04M derived: sum of 2 quarters · filed 2016-11-10 | $4.14M 10-Q · filed 2016-11-10 | ||
| 2016-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $2.50M 10-Q · filed 2016-08-11 | |||
| 2016-03-31 | $1.10M 10-Q · filed 2016-05-11 | ||||
| 2015-12-31 | $2.21M 10-K · filed 2018-03-07 | ||||
| 2014-12-31 | $22.00K 10-K · filed 2017-03-10 | ||||
| 2013-12-31 | $62.00K 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |